Quetiapine treatment for cannabis use disorder.

Adult Antipsychotic Agents / therapeutic use Cannabis Double-Blind Method Female Hallucinogens / therapeutic use Humans Male Marijuana Abuse / drug therapy Marijuana Smoking / drug therapy Middle Aged Outpatients Quetiapine Fumarate / therapeutic use Substance Withdrawal Syndrome / drug therapy Treatment Outcome
Cannabis use disorder Clinical trial Pharmacotherapy

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 20 06 2020
revised: 31 08 2020
accepted: 09 10 2020
pubmed: 7 11 2020
medline: 29 5 2021
entrez: 6 11 2020
Statut: ppublish

Résumé

Pharmacotherapy for cannabis use disorder (CUD) is an important unmet public health need. In a 12-week randomized double-blind placebo-controlled trial, the efficacy of quetiapine (300 mg nightly) for the treatment of CUD was tested in 130 outpatients. Weekly cannabis use was categorized into three groups: heavy use (5-7 days), moderate use (2-4 days) and light use (0-1 days). At baseline both groups were considered heavy users (using days per week: median = 7.0; interquartile range (IQR): 6.5-7.0; daily dollar value: median = $121.4; IQR: 73.8-206.3). The week-by-treatment interaction was marginally significant (χ The use of quetiapine to treat CUD was associated with an increased likelihood of heavy frequency use transitioning to moderate use, but not light use. The clinical significance of reductions in cannabis use, short of abstinence warrants further study.

Identifiants

DOI: 10.1016/j.drugalcdep.2020.108366 PMID: 33153828
pubmed: 33153828
pii: S0376-8716(20)30531-7
doi: 10.1016/j.drugalcdep.2020.108366
pii:
doi:

Substances chimiques

Antipsychotic Agents 0
Hallucinogens 0
Quetiapine Fumarate 2S3PL1B6UJ

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108366

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA031826
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

John J Mariani (JJ)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA. Electronic address: jm2330@columbia.edu.

Martina Pavlicova (M)

Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA.

C Jean Choi (C)

New York State Psychiatric Institute, Division of Mental Health Data Science, 1051 Riverside Drive, New York, NY, 10032, USA.

Cale Basaraba (C)

New York State Psychiatric Institute, Division of Mental Health Data Science, 1051 Riverside Drive, New York, NY, 10032, USA.

Kenneth M Carpenter (KM)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA.

Amy L Mahony (AL)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA.

Daniel J Brooks (DJ)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA.

Adam Bisaga (A)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA.

Nasir Naqvi (N)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA.

Edward V Nunes (EV)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA.

Frances R Levin (FR)

New York State Psychiatric Institute, Division on Substance Use Disorders, 1051 Riverside Drive, New York, NY, 10032, USA; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Neuroleptiques › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Rosanae › Rosales › Cannabaceae › Cannabis › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méthode en double aveugle › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Hallucinogènes › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Abus de marijuana › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Fumer › Fumer des produits autres que ceux du tabac › Fumer de la marijuana › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Personnes › Patients › Patients en consultation externe › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › Dibenzothiazépines › Fumarate de quétiapine › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Syndrome de sevrage › Quetiapine treatment for cannabis use disorder.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Quetiapine treatment for cannabis use disorder.